Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 214 entries
View as:

Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00898027 Org: User:
Start: 05/31/06 End: 02/28/09 Due: 02/28/10

Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00892801 Org: User:
Start: 05/31/09 End: 02/28/11 Due: 02/28/12

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01701037 Org: User:
Start: 01/31/13 End: 04/30/15 Due: 04/30/16

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04013880 Org: User:
Start: 08/27/19 End: 03/31/22 Due: 03/31/23

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT01096381 Org: User:
Start: 03/31/10 End: 08/31/11 Due: 08/31/12

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03583086 Org: User:
Start: 07/10/18 End: 04/27/24 Due: 04/27/25

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01240941 Org: User:
Start: 02/28/11 End: 12/31/12 Due: 12/31/13

Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT03415139 Org: User:
Start: 03/12/19 End: 04/30/25 Due: 04/30/26

MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01240928 Org: User:
Start: - End: - Due: -

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Phase: N/A Priority: Normal
NCT ID: NCT02493530 Org: User:
Start: 07/31/15 End: 05/31/24 Due: 05/31/25

Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer. (SPORE)

Phase: N/A Priority: Normal
NCT ID: NCT00898209 Org: User:
Start: 04/30/03 End: 12/31/09 Due: 12/31/10

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01316692 Org: User:
Start: 10/31/11 End: 08/31/15 Due: 08/31/16

Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00897832 Org: User:
Start: 01/31/07 End: 12/31/07 Due: 12/31/08

Immunoreactivity to Cetuximab in Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00896896 Org: User:
Start: 11/30/06 End: 10/31/08 Due: 10/31/09

Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00899002 Org: User:
Start: 07/31/07 End: 05/31/09 Due: 05/31/10

PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca

Phase: N/A Priority: Normal
NCT ID: NCT00467116 Org: User:
Start: 10/31/05 End: 10/31/07 Due: 10/31/08

A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC

Phase: N/A Priority: Normal
NCT ID: NCT00483821 Org: User:
Start: 05/31/04 End: 11/30/09 Due: 11/30/10

Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04883827 Org: User:
Start: 01/06/21 End: 12/01/23 Due: 12/01/24

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01918306 Org: User:
Start: 09/30/13 End: 04/30/15 Due: 04/30/16

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05919108 Org: User:
Start: 01/31/25 End: 04/30/31 Due: 04/30/32

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03566485 Org: User:
Start: 07/10/18 End: 12/10/20 Due: 12/10/21

Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis

Phase: N/A Priority: Normal
NCT ID: NCT02677883 Org: User:
Start: 01/31/16 End: 03/08/19 Due: 03/08/20

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01227018 Org: User:
Start: 12/31/10 End: 05/31/13 Due: 05/31/14

Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01276210 Org: User:
Start: 02/28/11 End: 06/30/17 Due: 06/30/18

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03924245 Org: User:
Start: 10/01/20 End: 02/04/22 Due: 02/04/23